Back to News
Market Impact: 0.3
Glaukos: IDose TR Plus Cataract Surgery Delivers Superior Eye Pressure Reduction In Phase 4 Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Glaukos reported positive topline results from a Phase 4 prospective randomized, controlled study of iDose TR administered alongside cataract surgery in patients with open-angle glaucoma or ocular hypertension. The article provides no numerical results or further details on the study outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
GKOS0.70
More News
- Glaukos: The Second J-Code Rewrites The Risk Math
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings